| 纯度 | ＞90% by SDS-PAGE. |
| 种属 | Human |
| 靶点 | AAMDC |
| Uniprot No | Q9H7C9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-122aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMTSPEIASLSWGQMKVKGSNTTYKDCK VWPGGSRTWDWRETGTEHSPGVQPADVKEVVEKGVQTLVIGRGMSEALKV PSSTVEYLKKHGIDVRVLQTEQAVKEYNALVAQGVRVGGVFHSTC |
| 预测分子量 | 16 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于AAMDC重组蛋白的示例参考文献(注：以下内容为基于领域知识的合理示例，具体文献需通过学术数据库验证)：
---
1. **文献名称**: *"Recombinant AAMDC Protein Promotes Breast Cancer Cell Proliferation via PI3K/AKT Signaling Activation"*
**作者**: Zhang Y, et al.
**摘要**: 本研究成功在大肠杆菌中表达并纯化了重组AAMDC蛋白，证实其通过激活PI3K/AKT通路显著促进乳腺癌细胞(如MCF-7)的增殖，为靶向AAMDC的癌症治疗提供了依据。
2. **文献名称**: *"Cloning and Functional Characterization of AAMDC in Adipocyte Differentiation"*
**作者**: Lee S, Kim JH.
**摘要**: 作者构建了AAMDC的重组表达载体，并在哺乳动物细胞中验证其功能，发现该蛋白通过调控PPARγ通路增强脂肪细胞分化，提示其在代谢疾病中的潜在作用。
3. **文献名称**: *"AAMDC Recombinant Protein Enhances Tumor Growth and Chemoresistance in Triple-Negative Breast Cancer Models"*
**作者**: Garcia-Rojas M, et al.
**摘要**: 通过体外和体内实验，证明重组AAMDC蛋白通过上调糖酵解相关基因(如HK2、LDHA)增强三阴性乳腺癌的化疗耐药性，为靶向代谢的疗法提供新思路。
4. **文献名称**: *"Structural and Biochemical Analysis of AAMDC Reveals Its Role in Lipid Metabolism"*
**作者**: Thompson R, et al.
**摘要**: 利用重组AAMDC蛋白进行结构解析(X射线晶体学)，发现其Mth938结构域与脂质合成酶相互作用，揭示了其在脂质代谢中的分子机制。
---
**建议**：实际文献检索可通过PubMed或Google Scholar使用关键词 **"AAMDC recombinant protein"** 或 **"AAMDC expression function"** 获取最新研究。
The AAMDC (Amplified in Mammary Disease Candidate) recombinant protein is derived from the AAMDC gene, a locus initially identified through genomic studies as a candidate oncogene frequently amplified in hormone receptor-positive (HR+) breast cancers. Located on chromosome 8q13. the AAMDC gene encodes a protein implicated in metabolic reprogramming and cell survival pathways, particularly under nutrient-stress conditions. Its overexpression correlates with endocrine therapy resistance and poor prognosis in breast cancer, suggesting a role in promoting tumor cell proliferation and evasion of therapy-induced apoptosis.
Structurally, the AAMDC protein contains conserved coiled-coil domains, enabling interactions with signaling mediators like mTOR and MYC pathways. These interactions facilitate metabolic adaptations, including enhanced glycolysis and lipid synthesis, which sustain cancer cell growth. Recombinant AAMDC protein is typically produced using bacterial (e.g., E. coli) or mammalian expression systems, engineered with affinity tags (e.g., His-tag) for purification. Its production enables functional studies to dissect molecular mechanisms, such as its role in stabilizing MYC proteins or modulating PI3K/AKT/mTOR signaling cascades.
Research applications include in vitro assays (e.g., protein-protein interaction studies, metabolic flux analyses) and in vivo tumor models to evaluate therapeutic targeting potential. As a biomarker, recombinant AAMDC aids in developing diagnostic tools for identifying HR+ breast cancer subtypes prone to therapy resistance. Ongoing studies explore its utility in designing inhibitors to disrupt AAMDC-mediated survival pathways, positioning it as a promising target for precision oncology in aggressive breast cancers.
×
